Nanotheranostics against COVID-19: From multivalent to immune-targeted materials

P Hassanzadeh - Journal of Controlled Release, 2020 - Elsevier
Destructive impacts of COVID-19 pandemic worldwide necessitates taking more appropriate
measures for mitigating virus spread and development of the effective theranostic agents. In …

Peptide vaccines for leishmaniasis

RCF De Brito, JMDO Cardoso, LES Reis… - Frontiers in …, 2018 - frontiersin.org
Due to an increase in the incidence of leishmaniases worldwide, the development of new
strategies such as prophylactic vaccines to prevent infection and decrease the disease have …

Experimental Validation of Multi-Epitope Peptides Including Promising MHC Class I- and II-Restricted Epitopes of Four Known Leishmania infantum Proteins

M Agallou, E Athanasiou, O Koutsoni… - Frontiers in …, 2014 - frontiersin.org
Leishmaniasis is a significant worldwide health problem for which no vaccine exists.
Activation of CD4+ and CD8+ T cells is crucial for the generation of protective immunity …

CD8+ T Cells in Leishmania Infections: Friends or Foes?

S Stäger, S Rafati - Frontiers in immunology, 2012 - frontiersin.org
Host protection against several intracellular pathogens requires the induction of CD8+ T cell
responses. CD8+ T cells are potent effector cells that can produce high amounts of pro …

A Poly(Lactic-co-Glycolic) Acid Nanovaccine Based on Chimeric Peptides from Different Leishmania infantum Proteins Induces Dendritic Cells Maturation and Promotes …

E Athanasiou, M Agallou, S Tastsoglou… - Frontiers in …, 2017 - frontiersin.org
Visceral leishmaniasis, caused by Leishmania (L.) donovani and L. infantum protozoan
parasites, can provoke overwhelming and protracted epidemics, with high case-fatality rates …

In silico analysis and in vivo assessment of a novel epitope-based vaccine candidate against uropathogenic Escherichia coli

S Hasanzadeh, M Habibi, MA Shokrgozar… - Scientific reports, 2020 - nature.com
Uropathogenic Escherichia coli (UPEC) are common pathogens in urinary tract infections
(UTIs), which show resistance to antibiotics. Therefore, there is a need for a vaccine to …

Visceral leishmaniasis: advancements in vaccine development via classical and molecular approaches

S Joshi, K Rawat, NK Yadav, V Kumar… - Frontiers in …, 2014 - frontiersin.org
Visceral leishmaniasis (VL) or kala-azar, a vector-borne protozoan disease, shows
endemicity in larger areas of the tropical, subtropical and the Mediterranean countries. WHO …

Identification of broadly conserved cross-species protective Leishmania antigen and its responding CD4+ T cells

Z Mou, J Li, T Boussoffara, H Kishi, H Hamana… - Science translational …, 2015 - science.org
There is currently no clinically effective vaccine against leishmaniasis because of poor
understanding of the antigens that elicit dominant T cell immunity. Using proteomics and …

Identification of HLA-I restricted epitopes in six vaccine candidates of Leishmania tropica using immunoinformatics and molecular dynamics simulation approaches

A Akya, A Farasat, K Ghadiri, M Rostamian - Infection, Genetics and …, 2019 - Elsevier
In spite of numerous studies on vaccination for various species of Leishmania, research on
the development of an effective vaccine for L. tropica is very scarce. In silico epitope …

Post-Genomics and Vaccine Improvement for Leishmania

N Seyed, T Taheri, S Rafati - Frontiers in microbiology, 2016 - frontiersin.org
Leishmaniasis is a parasitic disease that primarily affects Asia, Africa, South America, and
the Mediterranean basin. Despite extensive efforts to develop an effective prophylactic …